A novel study by Del Mastro and colleagues suggests that the occurrence of early menopause as a consequence of chemotherapy can be reduced by triptorelin-induced temporary ovarian suppression during chemotherapy in premenopausal patients with early-stage breast cancer. But does this treatment preserve fertility, and will the benefits of continued menstrual function outweigh the risks?
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Del Mastro, L. et al. Effect of the gonadotropin-releasing hormone analogue triptorelin on the occurrence of chemotherapy-induced early menopause in premenopausal women with breast cancer: a randomized trial. JAMA 306, 269–276 (2011).
Badawy, A. et al. Gonadotropin-releasing hormone agonists for prevention of chemotherapy-induced ovarian damage: prospective randomized study. Fertil. Steril. 91, 694–697 (2009).
Leonard, R. C. et al. The OPTION trial of adjuvant ovarian protection by goserelin in adjuvant chemotherapy for early breast cancer [abstract]. Proc. Am. Soc. Clin. Onc. 28 (Suppl.), a590 (2010).
Gerber, B. et al. Effect of luteinizing hormone-releasing hormone agonist on ovarian function after modern adjuvant breast cancer chemotherapy: the GBG 37 ZORO study. J. Clin. Oncol. 29, 2334–2341 (2011).
Ismail-Khan, R. et al. Preservation of ovarian function in young women treated with neoadjuvant chemotherapy for breast cancer: a randomized trial using the GnRH agonist (triptorelin) during chemotherapy [abstract]. J. Clin. Oncol. 26 (Suppl.), a524 (2008).
Broer, S. L. et al. Anti-Müllerian hormone predicts menopause: a long-term follow-up study in normoovulatory women. J. Clin. Endocrinol. Metab. 96, 2532–2539 (2011).
Anderson, R. A. & Cameron, D. A. Pretreatment serum anti-Müllerian hormone predicts long-term ovarian function and bone mass after chemotherapy for early breast cancer. J. Clin. Endocrinol. Metab. 96, 1336–1343 (2011).
Partridge, A. H. et al. Ovarian reserve in women who remain premenopausal after chemotherapy for early stage breast cancer. Fertil. Steril. 94, 638–644 (2010).
Partridge, A. H. et al. Web-based survey of fertility issues in young women with breast cancer. J. Clin. Oncol. 22, 4174–4183 (2004).
Swain, S. M. et al. Longer therapy, iatrogenic amenorrhea, and survival in early breast cancer. N. Engl. J. Med. 362, 2053–2065 (2010).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Rights and permissions
About this article
Cite this article
Ginsburg, E., Partridge, A. Triptorelin ovarian suppression during breast cancer chemotherapy. Nat Rev Endocrinol 7, 637–638 (2011). https://doi.org/10.1038/nrendo.2011.159
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrendo.2011.159
